KIT inhibition by Gleevec (imatinib) for severe asthma

May 26, 2017- Interviewed by Steven E. Greer, MD

Novartis’ Gleevec (imatinib) was approved in the U.S. in 2001 to treat leukemia. Now, researchers Continue reading

Posted in - Biotech, - NEJM, - Pharma, National Jewish Health, Pulmonology | Leave a comment

CheckMate 026: Why did Opdivo (nivolumab) fail in NSCLC?

September 1, 2016- Interviewed by Steven E. Greer, MD

In the wake of the news-making failure of CheckMate 026 of Bristol-Myers Squibb’s Opdivo (nivolumab) fail in Continue reading

Posted in - Biotech, - Pharma, Oncology, UCLA | Leave a comment

Insurance companies are not paying for Repatha and Praluent

March 8, 2017- Interviewed by Steven E. Greer, MD

We interviewed cardiologist William O’Neill, MD about his personal need for the cholesterol-lowering, large-molecule, antibody drug from Amgen, branded as Repatha. Despite Continue reading

Posted in - Biotech, - Pharma, - Policy, Cardiac surgery, Cardiology, Henry Ford, Primary care medicine | 1 Comment

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

January 12, 2017- Interviewed by Steven E. Greer, MD

Jonathan Strosberg, MD of Continue reading

Posted in - NEJM, Oncology | Leave a comment

The FDA pathway for biosimilar drug approvals

March 26, 2015- Interviewed by Steven E. Greer, MD

Posted in - Biotech, - Generics, FDA | Leave a comment

The MusiCorps benefit concert 2015

October 16, 2015- by Steven E. Greer, MD

We interviewed the Founder of MusiCorps, Arthur Bloom, and one of the musicians in the band, Continue reading

Posted in - Policy, NIH, Orthopedic surgery, Plastic surgery, Psychology Psychiatry, Trauma Surgery, VA Walter Reed | Leave a comment

Ocrelizumab (Ocrevus) versus Placebo in Primary Progressive Multiple Sclerosis

January 31, 2017- Interviewed by Steven E. Greer, MD Continue reading

Posted in - Biotech, - NEJM, - Pharma, Neurology, Univ Texas | 1 Comment

Aerobic or Resistance Exercise, or Both, in Dieting Obese Older Adults

June 14, 2017- Interviewed by Steven E. Greer, MD

We interviewed Dennis Villareal, MD, the author of the NEJM paper “Aerobic or Resistance Continue reading

Posted in - NEJM, Bariatric surgery, Baylor, Diabetes and endocrinology, Geriatrics, Internal Medicine | Leave a comment

The FDA’s new Breakthrough status for new drug applications

May 24, 2013- Interviewed by Steven E. Greer, MD

Janet Woodcock, MD, Continue reading

Posted in - Pharma, FDA | Leave a comment

BRAF and MEK combos for melanoma

Update October 1, 2015- The FDA approved the use of two drugs, Opdivo and Yervoy, to treat metastatic melanoma, as we first discussed with Dr. Ribas last year.  Continue reading

Posted in - Biotech, - Pharma, Oncology, UCLA | Leave a comment

Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis

May 23, 2017- interviewed by Steven E. Greer, MD

We interviewed polumonologist Michael Wechsler, MD about his paper in the NEJM testing mepolizumab Continue reading

Posted in - NEJM, National Jewish Health, Pulmonology, Rheumatology | Leave a comment

Are the new PCSK9 cholesterol lowering drugs worth the high cost?

December 16, 2015- Interviewed by Steven E. Greer, MD

Posted in - Biotech, - NEJM, - Opinion, - Pharma, - Policy, Cardiology, CMS, FDA | Leave a comment

Interview with MannKind’s CEO, Al Mann, and CFO, Matt Pfeffer.

October 23, 2013- Interviewed by Steven E. Greer, MD

The Healthcare Channel interviewed the CEO of MannKind, Al Mann, and the CFO, Matt Pfeffer. Continue reading

Posted in - Medical Devices, Diabetes and endocrinology, FDA | Leave a comment

How to establish a face transplant team

March 3, 2015- Interviewed by Steven E. Greer, MD

In Part 2 of our interview with Eduardo Rodriguez, MD, DDS, Chairman of Plastic Surgery at Continue reading

Posted in - Policy, NYU, Plastic surgery | Leave a comment

Trump made a big mistake wading into the quagmire of healthcare

Is President Obama foreseeing the future here and having a laugh?

May 7, 2017- Opinion by Steven E. Greer, MD

I watched Face the Nation and the news coverage of Friday town hall meetings. Mick Mulvaney was Continue reading

Posted in - Opinion, CMS, Congress | Leave a comment

The Daltrey Townshend teenage and young adult cancer center at UCLA

May 4, 2014- Interviewed by Steven E. Greer

More than 20 years ago, Roger Daltrey began forming special cancer units in the UK to treat patients in their teenage Continue reading

Posted in - Opinion, Oncology, Rehab, UCLA | Leave a comment

Single-pill combo regimens for HIV

July 28, 2014- Interviewed by Steven E. Greer, MD

Rajesh Tim Gandhi, MD of the Massachusetts General Hospital discusses the NEJM review paper Continue reading

Posted in - NEJM, Harvard, Infectious disease | Leave a comment

The Weekly Summary

August 28th – September 3rd                                 2017

In general news, Hurricane Harvey flooding in the Houston and Louisiana regions created the worst natural disaster in the history of the country, with estimates of damages close to $200 Billion. President Trump visited twice, receiving high marks. His new Chief of Staff, General John Kelly, was the previous Secretary of Homeland Security, which controls FEMA. In the economy, 156,000 new jobs were added in August, as manufacturing and consumer sentiment continue to rise. The GDP growth for last quarter was revised upward to 3%. Continue reading

Posted in - The Weekly Summary | Leave a comment

Vagal nerve stimulation for weight loss

January 22, 2015- Interviewed by Steven E. Greer, MD

Erik Dutson, MD, bariatric surgeon from UCLA, discusses the newly FDA-approved weight loss device called Continue reading

Posted in - Medical Devices, Bariatric surgery, Diabetes and endocrinology, Gastroenterology and liver, Primary care medicine, UCLA | Leave a comment

The ACA’s THC program: A pilot program to fund residency training outside of the traditional hospital setting

September 6, 2016- Interviewed by Steven E. Greer, MD

Posted in - NEJM, - Policy, CMS, George Washington Univ | Leave a comment